Chronic kidney disease and the global public health agenda: an international consensus
Safety, Tolerability, And Pharmacokinetics Of Antisense Oligonucleotide BIIB078 In Adults With C9orf72-associated Amyotrophic Lateral Sclerosis: A Phase 1, Randomised, Double ...
Institutions Authors Share Biogen, United States of America (USA)10.000000
10.000000
0.34 Ionis Pharmaceuticals, United States of America (USA)2.000000
0.07 University of Miami (UM), United States of America (USA)1.000000
0.03 University of Calgary (U of C), Canada1.000000
0.03 Sunnybrook Health Sciences Centre, U of T, Canada1.000000
0.03 University Medical Center Utrecht (UMC Utrecht), Netherlands1.000000
0.03 Woodruff Health Sciences Center (WHSC), Emory University, United States of America (USA)1.000000
0.03 Montreal Neurological Institute and Hospital (MNI), McGill University, Canada1.000000
0.03 The University of Dublin, Ireland1.000000
0.03 UC San Diego Health Sciences, United States of America (USA)1.000000
0.03 Johns Hopkins University (JHU), United States of America (USA)1.000000
0.03 Mayo Clinic's Campus in Florida, United States of America (USA)1.000000
0.03 Massachusetts General Hospital (MGH), United States of America (USA)1.000000
0.03 Kantonsspital St. Gallen, Switzerland1.000000
0.03 UK DRI at King's College London (UK DRI KCL), United Kingdom (UK)1.000000
0.03 NIHR University College London Hospitals Biomedical Research Centre, United Kingdom (UK)1.000000
0.03 Washington University in St. Louis (WUSTL), United States of America (USA)1.000000
0.03 Bryan Health, United States of America (USA)0.500000
0.02 The University of Sheffield, United Kingdom (UK)0.500000
0.02 NIHR Sheffield Biomedical Research Centre, United Kingdom (UK)0.500000
0.02 University of Nebraska Medical Center (UNMC), United States of America (USA)0.500000
0.02
Comments
Post a Comment